赝形δ掺杂 AlGaAs/InGa As/GaAs量子阱的光致发光性质研究

测量了一系列不同隔离层(spacer)厚度、阱宽和硅δ掺杂浓度的单边掺杂的赝形高电子迁移率晶体管(p-HEMTs)量子阱的变温和变激发功率光致发光谱，详细研究了(el-hh1)和(e2-hh1)两个发光峰之间的动态竞争发光机制，并运用有限差分法自洽求解薛定谔和泊松方程以得出电子限制势、子带能级以及相应的电子包络波函数、子带占据几率和δ掺杂电子转移效率，研究了两个峰的相对积分发光强度随隔离层厚度、阱宽和δ掺杂浓度的变化

新疆青海地区现代地表沉积物颜色指标与气候参数关系

为更好理解现代沉积物颜色指标(亮度L*、红度a*和黄度b*)与气候参数(年平均温度和年平均降水量)关系,采集新疆和青海地区大空间尺度上104个地表沉积物样品,运用空间分析与传统统计方法相结合探讨了颜色指标与气候参数的空间趋势特征及局部空间关系,并分析二者之间的相关性。研究发现无论是年平均温度和L*、a*和b*的趋势分析还是空间关联分析,年平均温度和L*、a*和b*在研究区域的不同地区具有不同的关系特征.年平均降水量和L*、a*和b*的趋势分析在研究区域的不同地区呈现负相关,空间关联分析中在东南部和中部年平均降水量与L*、a*和b*呈现负相关的关系特征.该地区现代表土沉积物颜色指标(L*、a*和b*)与年平均降水量呈负相关关系,相关系数分别为-0.26、-0.35和-0.29(P=0.01),与年平均温度相关性不显著,可能与年平均温度和颜色指标在研究区域的不同地区具有不同的相关性有关。现代地表沉积物颜色指标与气候参数的相关性高低,与采样点的数量、分布密度、跨度、地带性土壤类型、相关性分析方法等有关.本研究对新疆和青海地区地表沉积物颜色指标与气候参数之间关系的探讨,为深入探讨该地区地层颜色指标与古气候环境关系提供参考依据。</p

单边掺杂InAlAs／InGaAs单量子阱中二维电子气的磁输运特性

研究了双子带占据的In0.52Al0.48As／In0.53Ga0.47As单量子阱中磁电阻的Shubnikov-de Haas（SdH）振荡效应和霍耳效应，获得了不同子带电子的浓度、迁移率、有效质量和能级位置．低磁感应强度（B〈1．5T）下由迁移率谱和多载流子拟合相结合的方法得到的各子带电子浓度与通过SdH振荡得到的结果一致．在d^2ρ／dB^2-1／B的快速傅里叶变换谱中，观察到除了通常强烈依赖温度的对应于各子带的频率f1和f2以及f1的倍频（2f1）外，还观察到对温度不敏感的频率f1-f2．这是由于量子阱中不同子带的电子具有相近的有效质量，两个子带之间发生了强烈的磁致子带间散射

掺杂InGaAs/InAlAs单量子阱中电子对称态和反对称态磁输运研究

利用变温Hall测量研究了重掺杂InGaAs/InAlAs单量子阱中二维电子气,发现在量子阱中由于存在电子对称态和反对称态导致纵向电阻出现拍频现象.通过分析拍频节点位置,得到电子对称态和反对称态之间的能级间距为4meV.此外,通过迁移率谱方法和多载流子拟合过程研究了不同迁移率电子的浓度和迁移率随温度的变化关系

变In组分沟道的MM-HEMT材料电子输运特性研究

在变缓冲层高迁移率晶体管(MM-HEMT)器件中,二维电子气的输运性质对器件性能起着决定作用.通过低温下二维电子气横向电阻的量子振荡现象,结合变温度的Hall测量,系统研究了不同In组分沟道MM-HEMT器件中子带电子迁移率和浓度随温度的变化关系.结果表明,沟道中In组分为0.65的样品,材料电学性能最好,In组分高于0.65的样品,严重的晶格失配将产生位错,引起迁移率下降,大大影响材料和器件的性能

双δ掺杂In_(0.65)Ga_(0.35)As/In_(0.52)Al_(0.48)As赝型高迁移率晶体管材料子带电子特性研究

研究了基于InP基的In_(0.65)Ga_(0.35)As/In_(0.52)Al_(0.48)As赝型高迁移率晶体管材料中纵向磁电阻的Shubniko-de Haas (SdH)振荡效应和霍耳效应,通过对纵向磁电阻SdH振荡的快速傅里叶变换分析,获得了各子带电子的浓度,并因此求得了各子带能级相对于费米能级的位置.联立求解Schrodinger方程和Poisson方程,自洽计算了样品的导带形状、载流子浓度分布以及各子带能级和费米能级位置.理论计算和实验结果很好符合.实验和理论计算均表明,势垒层的掺杂电子几乎全部转移到了量子阱中,转移率在95%以上

InAlAs/InGaAs/InAlAs量子阱高迁移移率二维电子气系统中的反弱局域效应研究

研究了Si重δ掺杂In_(0.52)Al_(0.48)As/In_(0.53)Ga_(0.47)As/In_(0.52)Al_(0.48)As单量子阱内高迁移率二维电子气系统中的反弱局域效应.研究表明,强的Rashba自旋轨道相互作用来源于量子阱高的结构反演不对称.高迁移率系统中,粒子的运动基于弹道输运而非扩散输运.因此,旧的理论模型不能用于拟合实验结果.由于最新的模型在实际拟合中过于复杂,一种简单可行的近似用于处理实验结果,并获得了自旋分裂能△_0和自旋轨道耦合常数a两个重要的物理参数.该结果与对纵向电阻的Shubnikov-de Haas-SdH振荡分析获得的结果一致.高迁移率系统中的反弱局域效应研究表明,发展有效的反弱局域理论模型,对于利用Rashba自旋轨道相互作用来设计自旋器件尤为重要

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials